Amount of qualified sufferers: CDEC talked about the uncertainty in the amount of sufferers with moderately extreme to extreme hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some patients who are categorised as getting mild or average illness could have a severe bleeding phenotype,